Clinical and translational medicine · 2026
Mechanism of Gzma-mediated GEF-H1 activation in intestinal epithelial cells leading to intestinal barrier dysfunction in sepsis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Zexing, Jiang Haiyang, Ni Chujun, Deng Liting, Yang Huan, Wang Runnan, Liu Peizhao, Li Xuanheng, Yu Yilong, Li Weijie, Liao Bo, Liu Juanhan, Li Weizhen, Yang Jiaxin, Chao Yue, Liu Haiqing, Wu Xiuwen, Ren Jianan, Zhao Yun
Аннотация
BACKGROUND: Sepsis-induced intestinal injury is a severe complication associated with dysfunction affecting multiple organ systems and a significantly elevated risk of death. Intestinal barrier dysfunction plays a central role, but the underlying molecular pathways remain incompletely understood. The present study sought to explore how the Gzma/GEF-H1/RhoA signalling axis contributes to the disruption of the intestinal epithelial barrier in sepsis.
METHODS: Transcriptomic data, clinical samples, and a murine caecal ligation and puncture (CLP) model was used to assess Gzma expression and its correlation with disease severity. We investigated how Gzma-released by activated immune cells-affects epithelial structure and function using in vitro co-culture assays. These experiments assessed key tight junction proteins (occludin, claudin-1, ZO-1, E-cadherin), transepithelial electrical resistance (TEER), and paracellular permeability. GEF-H1 knockout mice and the GEF-H1 activator plinabulin were employed to evaluate the physiological roles of GEF-H1. Mutagenesis revealed how Gzma activates GEF-H1. High-throughput screening identified a GEF-H1 modulator, and its efficacy was validated in septic mice. Gzma expression was significantly elevated during sepsis and correlated with disease severity. Gzma secretion from immune cells impaired the epithelial barrier by downregulating tight junction proteins, increasing permeability, and reducing TEER. Gzma activates GEF-H1 by dephosphorylating Ser886, triggering the RhoA/ROCK pathway and subsequent phosphorylation of MLC2, LIMK, and cofilin-driving cytoskeletal remodelling. GEF-H1 knockout mice showed reduced intestinal injury, higher survival rates, and intact barrier function; conversely, GEF-H1 activation worsened intestinal damage. High-throughput screening identified Epothilone A as a potent GEF-H1 modulator that restores intestinal barrier integrity and improves survival in murine sepsis by suppressing the GEF-H1/librariesRhoA pathway.
CONCLUSION: This research uncovers the Gzma/GEF-H1/RhoA signalling axis as a pivotal contributor to intestinal barrier dysfunction during sepsis. GEF-H1 represents a promising therapeutic target, and its inhibition by agents such as Epothilone A may offer a novel strategy for treating sepsis.
KEY POINTS: Gzma induces the dephosphorylation of Ser886 on GEF-H1, activating the RhoA/ROCK pathway and disrupting the intestinal epithelial barrier. Knocking out GEF-H1 can alleviate intestinal damage, protect multiple organs, and increase the survival rate of septic mice. Epothilone A inhibits the activation of GEF-H1, thereby restoring the barrier function and reducing the mortality rate of sepsis.
METHODS: Transcriptomic data, clinical samples, and a murine caecal ligation and puncture (CLP) model was used to assess Gzma expression and its correlation with disease severity. We investigated how Gzma-released by activated immune cells-affects epithelial structure and function using in vitro co-culture assays. These experiments assessed key tight junction proteins (occludin, claudin-1, ZO-1, E-cadherin), transepithelial electrical resistance (TEER), and paracellular permeability. GEF-H1 knockout mice and the GEF-H1 activator plinabulin were employed to evaluate the physiological roles of GEF-H1. Mutagenesis revealed how Gzma activates GEF-H1. High-throughput screening identified a GEF-H1 modulator, and its efficacy was validated in septic mice. Gzma expression was significantly elevated during sepsis and correlated with disease severity. Gzma secretion from immune cells impaired the epithelial barrier by downregulating tight junction proteins, increasing permeability, and reducing TEER. Gzma activates GEF-H1 by dephosphorylating Ser886, triggering the RhoA/ROCK pathway and subsequent phosphorylation of MLC2, LIMK, and cofilin-driving cytoskeletal remodelling. GEF-H1 knockout mice showed reduced intestinal injury, higher survival rates, and intact barrier function; conversely, GEF-H1 activation worsened intestinal damage. High-throughput screening identified Epothilone A as a potent GEF-H1 modulator that restores intestinal barrier integrity and improves survival in murine sepsis by suppressing the GEF-H1/librariesRhoA pathway.
CONCLUSION: This research uncovers the Gzma/GEF-H1/RhoA signalling axis as a pivotal contributor to intestinal barrier dysfunction during sepsis. GEF-H1 represents a promising therapeutic target, and its inhibition by agents such as Epothilone A may offer a novel strategy for treating sepsis.
KEY POINTS: Gzma induces the dephosphorylation of Ser886 on GEF-H1, activating the RhoA/ROCK pathway and disrupting the intestinal epithelial barrier. Knocking out GEF-H1 can alleviate intestinal damage, protect multiple organs, and increase the survival rate of septic mice. Epothilone A inhibits the activation of GEF-H1, thereby restoring the barrier function and reducing the mortality rate of sepsis.